Wednesday 30th October 2019

Latest news from clinical trials of scleroderma treatments

The theme of Dr Voon Ong’s talk at SRUK’s Cambridge Conference in July was clinical trials in the field of emerging therapies, providing an overview of the latest news from recently completed clinical studies and of ongoing studies that show significant promise.

Read Article

Friday 25th October 2019

Can lung fibrosis be stopped?

Close to 70% of people living with systemic sclerosis develop interstitial lung disease, which often takes the form of pulmonary fibrosis. Recent research into protein inhibitors may lead to new therapeutic agents to treat pulmonary fibrosis.

Read Article

Tuesday 8th October 2019

Maxine Jackson's story

Hairdresser Maxine Jackson shares in this piece how she remains motivated to focus on her passions whilst overcoming the day-to-day challenges of scleroderma and the common misconceptions.

Read Article

Friday 4th October 2019

Physiotherapy exercises for systemic sclerosis: NHS physiotherapy guide

Physiotherapy relies on a variety of techniques to help restore movement and function when someone is affected by injury, illness or disability. Physiotherapy exercises are rapidly becoming a key management approach that can be taken to limit tightening of skin, which is characteristic to all forms of scleroderma.

Read Article

Tuesday 1st October 2019

Lizzi Hooks’ story

Proud mum Lizzi Hooks, 38, has lived with Raynaud’s phenomenon for most of her life, following self-diagnosis at the age of 14. Lizzi has told us her story to share how she manages daily tasks when her fingers fail her.

Read Article

Monday 23rd September 2019

Is botox an option for Raynaud’s?

Botox surgery is emerging as a form of treatment for Raynaud’s phenomenon, but the reasoning behind why this may work remains unclear. Research evaluating the use of Botulinum toxin type A (BoNT/A), one of the the main ingredients of Botox, has been steadily building since the early 2000s.

Read Article

Friday 13th September 2019

FDA approve drug for SSc-ILD: Ofev capsules

In an exciting step for scleroderma treatment, the USA’s Food and Drug Administration (FDA) have approved the use of nintedanib in treating interstitial lung disease associated with systemic sclerosis, making this the first therapy for those living with this condition caused by lung fibrosis.

Read Article

Friday 6th September 2019

Your employment support allowance stories

Many of our community will understand the difficulties that come with trying to secure disability benefits. As scleroderma is still a little known illness, it can take some hard work to secure the benefits you are entitled to. To help you figure out how to approach the process, we’ve asked members of our community to share their experiences.

Read Article

Friday 30th August 2019

The future of systemic sclerosis classification

A recent review published in Nature Rheumatology focused on research into the classification of scleroderma, which suggests that the current classification does not capture the heterogeneity of the condition.

Read Article

Thursday 22nd August 2019

Understanding vascular involvement in systemic sclerosis

In her talk at SRUK’s regional conference in Cambridge, Dr Robyn Domsic discussed a variety of topics that are crucial to understanding vascular involvement and expert recommendations on management.

Read Article